Osimertinib and Savolitinib Combination Shows Significant Survival Benefit in Non-Small Cell Lung Cancer

A new study, published in the New England Journal of Medicine, indicates that a combination of osimertinib and savolitinib significantly improves progression-free survival and overall survival in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on prior osimertinib treatment.